Alopecia induced by tumour necrosis factor-alpha antagonists: Description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database

Rheumatology (United Kingdom)

Volumn 53, Issue 8, 2014, Pages 1465-1469

  Béné, Johana ^a,b   Moulis, Guillaume ^c,d,e   Auffret, Marine ^a,b   Lefevre, Guillaume ^a   Coquerelle, Pascal ^f   Coupe, Patrick ^g   Péré, Patrice ^h   Gautier, Sophie ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE TOULOUSE   (France)

^e Faculté de Médecine Centre Hospitalo universitaire   (France)

^f Rheumatology Department Bethune Hospital   (India)

^g CENTRE HOSPITALIER DE VALENCIENNES   (France)

^h UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Adalimumab; Adverse drug reaction; Alopecia; Disproportionality analysis; Etanercept; Infliximab; TNF antagonist

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; DOCETAXEL; ETANERCEPT; INFLIXIMAB; PARACETAMOL; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ADVERSE DRUG REACTION; ALOPECIA; ARTICLE; DRUG EXPOSURE; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROCEDURES;

ADALIMUMAB; ADVERSE DRUG REACTION; ALOPECIA; DISPROPORTIONALITY ANALYSIS; ETANERCEPT; INFLIXIMAB; TNF-Α ANTAGONIST;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ALOPECIA; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; DATABASES, FACTUAL; FEMALE; FRANCE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; MALE; PHARMACOVIGILANCE; POLYETHYLENE GLYCOLS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904883566     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu145     Document Type: Article

References (27)

1. Wong M, Ziring D, Korin Y et al. TNFa blockade in human diseases: mechanisms and future directions. Clin Immunol 2008;126:121-36.
2. Ettefagh L, Nedorost S, Mirmirani P. Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol 2004;140:1012.
3. Posten W, Swan J. Recurrence of alopecia areata in a patient receiving etanercept injections. Arch Dermatol 2005;141:759-60.
4. Garcia Bartels N, Lee HH, Worm M et al. Development of alopecia areata universalis in a patient receiving adalimumab. Arch Dermatol 2006;142:1654-5.
5. Tosti A, Pazzaglia M, Starace M et al. Alopecia areata during treatment with biologic agents. Arch Dermatol 2006;142:1653-4.
6. Chaves Y, Duarte G, Ben-Said B et al. Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab). Dermatology 2008;217:380.
7. Pelivani N, Hassan AS, Braathen LR, Hunger RE, Yawalkar N. Alopecia areata universalis elicited during treatment with adalimumab. Dermatology 2008;216:320-3.
8. Fabre C, Dereure O. Worsening alopecia areata and de novo occurrence of multiple halo nevi in a patient receiving infliximab. Dermatology 2008;216:185-6.
9. Hernández MV, Nogués S, Ruiz-Esquide V et al. Development of alopecia areata after biological therapy with TNF-alpha blockers: description of a case and review of the literature. Clin Exp Rheumatol 2009;27:892-3.
10. Nakagomi D, Harada K, Yagasaki A et al. Psoriasiform eruption associated with alopecia areata during infliximab therapy. Clin Exp Dermatol 2009;34:923-4.
11. Kirshen C, Kanigsberg N. Alopecia areata following adalimumab. J Cutan Med Surg 2009;13:48-50.
12. Beccastrini E, Squatrito D, Emmi G, Fabbri P, Emmi L. Alopecia areata universalis during off-label treatment with Infliximab in a patient with Behçet disease. Dermatol Online J 2010;16:15.
13. Le Bidre E, Chaby G, Martin L et al. Alopecia areata during anti-TNF alpha therapy: nine cases. Ann Dermatol Venereol 2011;138:285-93.
14. Ferran M, Calvet J, Almirall M, Pujol RM, Maymó J. Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-a blocker agents: report of five cases and review of the literature. J Eur Acad Dermatol Venereol 2011;25:479-84.
15. Moore N, Noblet C, Kreft-Jais C et al. French pharmacovigilance database system: examples of utilisation. Therapie 1995;50:557-62.
16. Spreux A, Baldin B, Chichmanian RM. Pharmacovigilance in practice. Transfus Clin Biol 1999;6:254-9.
17. Bégaud B, Evreux JC, Jouglard J, Lagier G. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. Therapie 1985;40:111-8.
18. Montastruc JL, Sommet A, Bagheri H et al. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 2011;72:905-8.
19. Moore N, Kreft-Jais C, Haramburu F et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol 1998;44:513-8.
20. Egberts AC, Meyboom RH, van Puijenbroek EP. Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf 2002;25:453-8.
21. Weinblatt ME. Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol Suppl 1985;12:35-9.
22. Gottenberg JE, Venancie PY, Mariette X. Alopecia areata in a patient with rheumatoid arthritis treated with leflunomide. J Rheumatol 2002;29:1806-7.
23. Phillips MA, Graves JE, Nunley JR. Alopecia areata presenting in 2 kidney-pancreas transplant recipients taking cyclosporine. J Am Acad Dermatol 2005;53: S252-5.
24. Joly P. The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis. J Am Acad Dermatol 2006;55:632-6.
25. Bégaud B, Martin K, Haramburu F, Moore N. Rates of spontaneous reporting of adverse drug reactions in France. JAMA 2002;288:1588.
26. Philpott MP, Sanders DA, Bowen J, Kealy T. Effects of interleukins, colony-stimulating factor and tumour necrosis factor on human hair follicle growth in vitro: a possible role for interleukin-1 and tumour necrosis factor-alpha in alopecia areata. Br J Dermatol 1996;135:942-8.
27. Strober BE, Siu K, Alexis AF et al. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. J Am Acad Dermatol 2005;52:1082-4.